Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma

Authors: Ales Sedlar, Simona Kranjc, Tanja Dolinsek, Maja Cemazar, Andrej Coer, Gregor Sersa

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Interleukin-12 (IL-12) based radiosensitization is an effective way of tumor treatment. Local cytokine production, without systemic shedding, might provide clinical benefit in radiation treatment of sarcomas. Therefore, the aim was to stimulate intratumoral IL-12 production by gene electrotransfer of plasmid coding for mouse IL-12 (mIL-12) into the tumors, in order to explore its radiosensitizing effect after single or multiple intratumoral gene electrotransfer.

Methods

Solid SA-1 fibrosarcoma tumors, on the back of A/J mice, were treated intratumorally by mIL-12 gene electrotransfer and 24 h later irradiated with a single dose. Treatment effectiveness was measured by tumor growth delay and local tumor control assay (TCD50 assay). With respect to therapeutic index, skin reaction in the radiation field was scored. The tumor and serum concentrations of cytokines mIL-12 and mouse interferon γ (mIFNγ) were measured. Besides single, also multiple intratumoral mIL-12 gene electrotransfer before and after tumor irradiation was evaluated.

Results

Single intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral but not serum mIL-12 and mIFNγ concentrations, and had good antitumor (7.1% tumor cures) and radiosensitizing effect (21.4% tumor cures). Combined treatment resulted in the radiation dose-modifying factor of 2.16. Multiple mIL-12 gene electrotransfer had an even more pronounced antitumor (50% tumor cures) and radiosensitizing (86.7% tumor cures) effect.

Conclusions

Single or multiple intratumoral mIL-12 gene electrotransfer resulted in increased intratumoral mIL-12 and mIFNγ cytokine level, and may provide an efficient treatment modality for soft tissue sarcoma as single or adjuvant therapy to tumor irradiation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies. Strahlenther Onkol. 2004, 180: 331-339. 10.1007/s00066-004-8119-1.CrossRefPubMed Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies. Strahlenther Onkol. 2004, 180: 331-339. 10.1007/s00066-004-8119-1.CrossRefPubMed
2.
go back to reference Sersa G, Willingham V, Milas L: Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer. 1988, 42: 129-134. 10.1002/ijc.2910420124.CrossRefPubMed Sersa G, Willingham V, Milas L: Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer. 1988, 42: 129-134. 10.1002/ijc.2910420124.CrossRefPubMed
3.
go back to reference Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997, 90: 2541-2548.PubMed Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997, 90: 2541-2548.PubMed
5.
go back to reference Kamensek U, Sersa G: Targeted gene therapy in radiotherapy. Radiol Oncol. 2008, 42: 115-135. 10.2478/v10019-008-0009-1.CrossRef Kamensek U, Sersa G: Targeted gene therapy in radiotherapy. Radiol Oncol. 2008, 42: 115-135. 10.2478/v10019-008-0009-1.CrossRef
6.
go back to reference Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Strahlenther Onkol. 2004, 180: 187–-193.CrossRefPubMed Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F: Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Strahlenther Onkol. 2004, 180: 187–-193.CrossRefPubMed
7.
go back to reference Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3: 133-146. 10.1038/nri1001.CrossRefPubMed Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003, 3: 133-146. 10.1038/nri1001.CrossRefPubMed
8.
go back to reference Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY: Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther. 2000, 2: 195-203. 10.1006/mthe.2000.0114.CrossRefPubMed Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY: Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther. 2000, 2: 195-203. 10.1006/mthe.2000.0114.CrossRefPubMed
9.
go back to reference Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR: Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999, 15: 769-773.PubMed Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR: Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999, 15: 769-773.PubMed
10.
go back to reference De Ridder M, Verellen D, Verovski V, Storme G: Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide. 2008, 19: 164-169. 10.1016/j.niox.2008.04.015.CrossRefPubMed De Ridder M, Verellen D, Verovski V, Storme G: Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide. 2008, 19: 164-169. 10.1016/j.niox.2008.04.015.CrossRefPubMed
11.
go back to reference Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Yang G, et al: Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther. 2007, 14: 227-236. 10.1038/sj.gt.3302788.CrossRefPubMed Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Yang G, et al: Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther. 2007, 14: 227-236. 10.1038/sj.gt.3302788.CrossRefPubMed
12.
go back to reference Kim W, Seong J, Oh HJ, Koom WS, Choi KJ, Yun CO: A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res (Tokyo). 2011, 52: 646-654. 10.1269/jrr.10185.CrossRef Kim W, Seong J, Oh HJ, Koom WS, Choi KJ, Yun CO: A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res (Tokyo). 2011, 52: 646-654. 10.1269/jrr.10185.CrossRef
13.
go back to reference Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, Li CY: Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys. 2000, 48: 1513-1518. 10.1016/S0360-3016(00)00788-4.CrossRefPubMed Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, Li CY: Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys. 2000, 48: 1513-1518. 10.1016/S0360-3016(00)00788-4.CrossRefPubMed
14.
go back to reference Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW, et al: A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther. 2007, 6: 380-389. 10.1158/1535-7163.MCT-06-0342.CrossRefPubMed Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW, et al: A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther. 2007, 6: 380-389. 10.1158/1535-7163.MCT-06-0342.CrossRefPubMed
15.
go back to reference Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG: Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig. 1998, 6: 71-80. 10.1002/(SICI)1520-6823(1998)6:2<71::AID-ROI2>3.0.CO;2-E.CrossRefPubMed Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG: Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig. 1998, 6: 71-80. 10.1002/(SICI)1520-6823(1998)6:2<71::AID-ROI2>3.0.CO;2-E.CrossRefPubMed
16.
go back to reference Teicher BA, Ara G, Menon K, Schaub RG: In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer. 1996, 65: 80-84. 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M.CrossRefPubMed Teicher BA, Ara G, Menon K, Schaub RG: In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer. 1996, 65: 80-84. 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M.CrossRefPubMed
17.
go back to reference Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, Vidic S, Pavlin D, Sersa G: Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med. 2009, 11: 1125-1137. 10.1002/jgm.1403.CrossRefPubMed Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, Vidic S, Pavlin D, Sersa G: Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med. 2009, 11: 1125-1137. 10.1002/jgm.1403.CrossRefPubMed
18.
go back to reference Xian J, Yang H, Lin Y, Liu S: Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005, 131: 1079-1085. 10.1001/archotol.131.12.1079.CrossRefPubMed Xian J, Yang H, Lin Y, Liu S: Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005, 131: 1079-1085. 10.1001/archotol.131.12.1079.CrossRefPubMed
19.
go back to reference Yang Y, Liu SZ, Fu SB: Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms. Biomed Environ Sci. 2004, 17: 135-143.PubMed Yang Y, Liu SZ, Fu SB: Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms. Biomed Environ Sci. 2004, 17: 135-143.PubMed
20.
go back to reference Cemazar M, Jarm T, Sersa G: Cancer electrogene therapy with interleukin-12. Curr Gene Ther. 2010, 10: 300-311. 10.2174/156652310791823425.CrossRefPubMed Cemazar M, Jarm T, Sersa G: Cancer electrogene therapy with interleukin-12. Curr Gene Ther. 2010, 10: 300-311. 10.2174/156652310791823425.CrossRefPubMed
21.
go back to reference Heller LC, Heller R: Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther. 2010, 10: 312-317. 10.2174/156652310791823489.CrossRefPubMed Heller LC, Heller R: Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther. 2010, 10: 312-317. 10.2174/156652310791823489.CrossRefPubMed
22.
go back to reference Kanduser M, Miklavcic D, Pavlin M: Mechanisms involved in gene electrotransfer using high- and low-voltage pulses–an in vitro study. Bioelectrochemistry. 2009, 74: 265-271. 10.1016/j.bioelechem.2008.09.002.CrossRefPubMed Kanduser M, Miklavcic D, Pavlin M: Mechanisms involved in gene electrotransfer using high- and low-voltage pulses–an in vitro study. Bioelectrochemistry. 2009, 74: 265-271. 10.1016/j.bioelechem.2008.09.002.CrossRefPubMed
23.
go back to reference Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008, 26: 5896-5903.CrossRefPubMedPubMedCentral Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008, 26: 5896-5903.CrossRefPubMedPubMedCentral
24.
go back to reference Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N: Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol. 2011, 45: 31-39. 10.2478/v10019-010-0041-9.CrossRefPubMed Pavlin D, Cemazar M, Cör A, Sersa G, Pogacnik A, Tozon N: Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol. 2011, 45: 31-39. 10.2478/v10019-010-0041-9.CrossRefPubMed
25.
go back to reference Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, Budach W: Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol. 2010, 5: 55-10.1186/1748-717X-5-55.CrossRefPubMedPubMedCentral Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, Budach W: Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol. 2010, 5: 55-10.1186/1748-717X-5-55.CrossRefPubMedPubMedCentral
26.
go back to reference Kaushal A, Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 2008, 88: 629-646. 10.1016/j.suc.2008.03.005. viiiCrossRefPubMedPubMedCentral Kaushal A, Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 2008, 88: 629-646. 10.1016/j.suc.2008.03.005. viiiCrossRefPubMedPubMedCentral
27.
go back to reference Kepka L, DeLaney TF, Suit HD, Goldberg SI: Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005, 63: 852-859. 10.1016/j.ijrobp.2005.03.004.CrossRefPubMed Kepka L, DeLaney TF, Suit HD, Goldberg SI: Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005, 63: 852-859. 10.1016/j.ijrobp.2005.03.004.CrossRefPubMed
28.
go back to reference Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G: Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther. 2009, 8: 2114-2122. 10.4161/cbt.8.22.9734.CrossRefPubMed Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G: Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther. 2009, 8: 2114-2122. 10.4161/cbt.8.22.9734.CrossRefPubMed
29.
go back to reference Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Mesojednik S, Rols MP, Teissie J: Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther. 2009, 16: 635-644. 10.1038/gt.2009.10.CrossRefPubMed Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Mesojednik S, Rols MP, Teissie J: Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther. 2009, 16: 635-644. 10.1038/gt.2009.10.CrossRefPubMed
30.
go back to reference Cemazar M, Pavlin D, Kranjc S, Grosel A, Mesojednik S, Sersa G: Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Curr Drug Deliv. 2006, 3: 77-81. 10.2174/156720106775197556.CrossRefPubMed Cemazar M, Pavlin D, Kranjc S, Grosel A, Mesojednik S, Sersa G: Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Curr Drug Deliv. 2006, 3: 77-81. 10.2174/156720106775197556.CrossRefPubMed
31.
go back to reference Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G: Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat Res. 2009, 172: 677-685. 10.1667/RR1873.1.CrossRefPubMed Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G: Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat Res. 2009, 172: 677-685. 10.1667/RR1873.1.CrossRefPubMed
32.
go back to reference Sersa G, Cemazar M, Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995, 55: 3450-3455.PubMed Sersa G, Cemazar M, Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995, 55: 3450-3455.PubMed
33.
go back to reference Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989, 24: 148-154. 10.1007/BF00300234.CrossRefPubMed Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989, 24: 148-154. 10.1007/BF00300234.CrossRefPubMed
34.
go back to reference Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H, Himmelreich U, Stenzel W, Jacobs AH, von Laer D: Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res. 2007, 13: 6761-6768. 10.1158/1078-0432.CCR-07-1240.CrossRefPubMed Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H, Himmelreich U, Stenzel W, Jacobs AH, von Laer D: Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res. 2007, 13: 6761-6768. 10.1158/1078-0432.CCR-07-1240.CrossRefPubMed
35.
go back to reference Sersa G, Kranjc S, Cemazar M: Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys. 2000, 46: 1037-1041. 10.1016/S0360-3016(99)00464-2.CrossRefPubMed Sersa G, Kranjc S, Cemazar M: Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys. 2000, 46: 1037-1041. 10.1016/S0360-3016(99)00464-2.CrossRefPubMed
36.
go back to reference Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13: 155-168. 10.1016/S1359-6101(01)00032-6.CrossRefPubMed Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13: 155-168. 10.1016/S1359-6101(01)00032-6.CrossRefPubMed
37.
go back to reference Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998, 392: 86-89. 10.1038/32183.CrossRefPubMed Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998, 392: 86-89. 10.1038/32183.CrossRefPubMed
38.
go back to reference Liu SZ, Jin SZ, Liu XD, Sun YM: Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol. 2001, 2: 8-10.1186/1471-2172-2-8.CrossRefPubMedPubMedCentral Liu SZ, Jin SZ, Liu XD, Sun YM: Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol. 2001, 2: 8-10.1186/1471-2172-2-8.CrossRefPubMedPubMedCentral
39.
go back to reference Lucas ML, Heller L, Coppola D, Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002, 5: 668-675. 10.1006/mthe.2002.0601.CrossRefPubMed Lucas ML, Heller L, Coppola D, Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002, 5: 668-675. 10.1006/mthe.2002.0601.CrossRefPubMed
40.
go back to reference Shi X, Cao S, Mitsuhashi M, Xiang Z, Ma X: Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol. 2004, 172: 4111-4122.CrossRefPubMedPubMedCentral Shi X, Cao S, Mitsuhashi M, Xiang Z, Ma X: Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol. 2004, 172: 4111-4122.CrossRefPubMedPubMedCentral
41.
go back to reference North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE: Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med. 1988, 168: 2031-2043. 10.1084/jem.168.6.2031.CrossRefPubMed North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE: Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med. 1988, 168: 2031-2043. 10.1084/jem.168.6.2031.CrossRefPubMed
42.
go back to reference Grosel A, Sersa G, Kranjc S, Cemazar M: Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell Biol. 2006, 25: 674-683. 10.1089/dna.2006.25.674.CrossRefPubMed Grosel A, Sersa G, Kranjc S, Cemazar M: Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell Biol. 2006, 25: 674-683. 10.1089/dna.2006.25.674.CrossRefPubMed
43.
go back to reference Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, Blagus T, Cemazar M, Sersa G: Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol. 2012, 46: 302-311.CrossRefPubMedPubMedCentral Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, Blagus T, Cemazar M, Sersa G: Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol. 2012, 46: 302-311.CrossRefPubMedPubMedCentral
44.
go back to reference Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G: Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res. 2003, 23: 275-281.PubMed Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G: Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res. 2003, 23: 275-281.PubMed
45.
go back to reference Kranjc S, Cemazar M, Grosel A, Sentjurc M, Sersa G: Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer. 2005, 5: 115-10.1186/1471-2407-5-115.CrossRefPubMedPubMedCentral Kranjc S, Cemazar M, Grosel A, Sentjurc M, Sersa G: Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer. 2005, 5: 115-10.1186/1471-2407-5-115.CrossRefPubMedPubMedCentral
46.
go back to reference Raeisi E, Aghamiri SMR, Bandi A, Rahmatpour N, Firoozabadi SM, Kafi-Abad SA, Mir LM: The antitumor efficiency of combined electrochemotherapy and single dose irradiation on a breast cancer tumor model. Radiol Oncol. 2012, 46: 226-232. 10.2478/v10019-012-0035-x.CrossRefPubMedPubMedCentral Raeisi E, Aghamiri SMR, Bandi A, Rahmatpour N, Firoozabadi SM, Kafi-Abad SA, Mir LM: The antitumor efficiency of combined electrochemotherapy and single dose irradiation on a breast cancer tumor model. Radiol Oncol. 2012, 46: 226-232. 10.2478/v10019-012-0035-x.CrossRefPubMedPubMedCentral
Metadata
Title
Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma
Authors
Ales Sedlar
Simona Kranjc
Tanja Dolinsek
Maja Cemazar
Andrej Coer
Gregor Sersa
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-38

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine